Search research articles
Contact Us
Filters
Showing results (51-60 of 338) with videos related to
Page
of 34
Sort By:
The Lancet. Oncology
|
December 8, 2016
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T Gibney, Louis M Weiner, Michael B Atkins
Clinical Genitourinary Cancer
|
October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials
David F McDermott, Meredith M Regan, Michael B Atkins
BMC Medicine
|
February 7, 2016
Advances in immunotherapy for melanoma
Jason M Redman, Geoffrey T Gibney, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2006
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
David J Panka, Michael B Atkins, James W Mier
The Oncologist
|
March 1, 2018
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
Nizar M Tannir, Sumanta K Pal, Michael B Atkins
Journal of Translational Medicine
|
July 5, 2015
What's new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola, Michael B Atkins
Cancers
|
February 15, 2022
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
Eric Jonasch, Michael B Atkins, Simon Chowdhury, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
January 24, 2014
New options and new questions: how to select and sequence therapies for patients with metastatic melanoma
Keith T Flaherty, Jeff A Sosman, Michael B Atkins
Journal for Immunotherapy of Cancer
|
May 22, 2020
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
Michael T Serzan, Princy N Kumar, Michael B Atkins
European Urology
|
June 30, 2023
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116
Meredith M Regan, Michael B Atkins, David F McDermott
Page
of 34
Search research articles
Search
Showing results (51-60 of 338) with videos related to
Sort By:
Page
of 34
The Lancet. Oncology
|
December 8, 2016
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T Gibney, Louis M Weiner, Michael B Atkins
Clinical Genitourinary Cancer
|
October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials
David F McDermott, Meredith M Regan, Michael B Atkins
BMC Medicine
|
February 7, 2016
Advances in immunotherapy for melanoma
Jason M Redman, Geoffrey T Gibney, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2006
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
David J Panka, Michael B Atkins, James W Mier
The Oncologist
|
March 1, 2018
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
Nizar M Tannir, Sumanta K Pal, Michael B Atkins
Journal of Translational Medicine
|
July 5, 2015
What's new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola, Michael B Atkins
Cancers
|
February 15, 2022
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
Eric Jonasch, Michael B Atkins, Simon Chowdhury, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
January 24, 2014
New options and new questions: how to select and sequence therapies for patients with metastatic melanoma
Keith T Flaherty, Jeff A Sosman, Michael B Atkins
Journal for Immunotherapy of Cancer
|
May 22, 2020
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
Michael T Serzan, Princy N Kumar, Michael B Atkins
European Urology
|
June 30, 2023
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116
Meredith M Regan, Michael B Atkins, David F McDermott
Page
of 34